Company Profile
PureTech Health Stock Price, News & Catalysts
- Ticker:
- PRTC
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United Kingdom
Stock performance
17.42 USD (+1.99%)
Close
Last updated: May 20, 2026
424M USD
Market cap
Why the stock is moving
Current closing-price context is not available for PRTC.
Company overview
Founded-Entity Model
PureTech Health creates and advances biotechnology companies around internally identified scientific concepts. Rather than operating as a conventional single-pipeline developer, it retains ownership interests and economic rights across a portfolio of independently financed founded entities.
Celea Therapeutics
Celea is developing deupirfenidone, formerly LYT-100, for idiopathic pulmonary fibrosis. The deuterated pirfenidone candidate completed the Phase 2b ELEVATE IPF study and is Phase 3 ready for the head-to-head SURPASS-IPF trial against pirfenidone.
Gallop Oncology
Gallop is advancing LYT-200, an anti-galectin-9 antibody, for relapsed or refractory myeloid malignancies. Phase 1b data in high-risk myelodysplastic syndrome and acute myeloid leukemia provide clinical validation for a planned next stage of development.
Seaport Therapeutics
Seaport applies the Glyph platform to neuropsychiatric medicines designed for lymphatic transport and enhanced exposure. Its pipeline includes GlyphAllo for major depressive disorder and GlyphAgo for generalized anxiety disorder and associated sleep disturbance.
Portfolio Value Creation
PureTech seeks to create value by separating programs into focused companies, attracting external capital and partners, and retaining equity or contractual economics. This structure allows different assets to progress with dedicated management and financing.
Future catalysts
- Initiation of Celea’s Phase 3 SURPASS-IPF trial near the closing of its planned financing.
- Topline Phase 2b BUOY-1 data for GlyphAllo expected in the first half of 2027.
- Phase 2a GlyphAgo sleep-study results expected in early 2028 and Phase 2b GAD results expected by year-end 2028.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of PureTech Health (PRTC)?
PureTech Health (PRTC) most recently closed at 17.42 USD, a +1.99% move versus the previous session.
What is the market cap of PureTech Health (PRTC)?
PureTech Health currently has a market capitalization of 424M USD on BioPharmSignal.
What does PureTech Health do?
Founded-Entity Model PureTech Health creates and advances biotechnology companies around internally identified scientific concepts. Rather than operating as a conventional single-pipeline developer, it retains ownership interests and economic rights across a portfolio of independently financed founded entities. Celea Therapeutics Celea is developing...
On which exchange is PRTC stock listed?
PureTech Health (PRTC) is associated with NASDAQ, United Kingdom, Biopharma.
What is LYT-100?
Celea Therapeutics Celea is developing deupirfenidone, formerly LYT-100, for idiopathic pulmonary fibrosis.
Which conditions is PureTech Health targeting with LYT-100?
PureTech Health is associated with oncology based on its company overview and current catalyst commentary.
How does PureTech Health describe recent progress with LYT-100?
Initiation of Celea’s Phase 3 SURPASS-IPF trial near the closing of its planned financing. Topline Phase 2b BUOY-1 data for GlyphAllo expected in the first half of 2027. Phase 2a GlyphAgo sleep-study results expected in early 2028 and Phase 2b GAD results expected by year-end 2028.
What is SURPASS-IPF?
The deuterated pirfenidone candidate completed the Phase 2b ELEVATE IPF study and is Phase 3 ready for the head-to-head SURPASS-IPF trial against pirfenidone.